AI-generated analysis. Always verify with the original filing.
A critical inflection year marked by accelerating losses and near-exhaustion of liquidity as the company advanced its lead asset toward regulatory submission, though positive Phase IIb survival data provides a path to potential approval.
EPS
$-0.98
Net Income
-$28.8M
Operating Income
-$28.7M